Literature DB >> 16790316

Suppressive treatment of abamectin against Dictyocaulus viviparus and the occurrence of resistance in first-grazing-season calves.

M B Molento1, R A Depner, M H A Mello.   

Abstract

Dictyocaulus viviparus cause severe lung infections and are endemic in some areas of temperate and tropical countries. Treatment is based on strategic nematode control programs using potent compounds with no reports of drug failure. Macrocyclic lactones (MLs) are available at different concentrations and combinations and have being used heavily by producers. The objective of this work was to determine the efficacy of the MLs ivermectin, moxidectin, doramectin, and abamectin, and the combination ivermectin plus abamectin in naturally infected calves (n=70). Initial infection was determined by necropsy of tracer animals. Faecal larval counts determined that none of the compounds used was able to eliminate D. viviparus for up to 28 days after treatment. The "Area Nova" strain was isolated for future work.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790316     DOI: 10.1016/j.vetpar.2006.01.061

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  3 in total

Review 1.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

Review 2.  Deep insights into Dictyocaulus viviparus transcriptomes provides unique prospects for new drug targets and disease intervention.

Authors:  Cinzia Cantacessi; Robin B Gasser; Christina Strube; Thomas Schnieder; Aaron R Jex; Ross S Hall; Bronwyn E Campbell; Neil D Young; Shoba Ranganathan; Paul W Sternberg; Makedonka Mitreva
Journal:  Biotechnol Adv       Date:  2010-12-22       Impact factor: 14.227

3.  Dictyocaulus viviparus genome, variome and transcriptome elucidate lungworm biology and support future intervention.

Authors:  Samantha N McNulty; Christina Strübe; Bruce A Rosa; John C Martin; Rahul Tyagi; Young-Jun Choi; Qi Wang; Kymberlie Hallsworth Pepin; Xu Zhang; Philip Ozersky; Richard K Wilson; Paul W Sternberg; Robin B Gasser; Makedonka Mitreva
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.